{
    "Trade/Device Name(s)": [
        "B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S CgA II KRYPTOR",
        "B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S CgA II KRYPTOR CAL",
        "B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S CgA II KRYPTOR QC"
    ],
    "Submitter Information": "B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S GmbH, part of Thermo Fisher Scientific",
    "510(k) Number": "K222251",
    "Predicate Device Reference 510(k) Number(s)": [
        "K990774",
        "K171338"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QXS",
        "PMT",
        "PRI",
        "NMT",
        "JZT"
    ],
    "Summary Letter Date": "September 18, 2023",
    "Summary Letter Received Date": "May 11, 2023",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.6010",
        "21 CFR 862.1660",
        "21 CFR 862.1150",
        "21 CFR 866.4520"
    ],
    "Regulation Name(s)": [
        "Tumor-associated antigen immunological test system",
        "Quality Control material (assayed and unassayed)",
        "Calibrator",
        "Immunofluorometer equipment"
    ],
    "Analyte Class(es)": [
        "immunology",
        "anatomic pathology"
    ],
    "Analyte(s)": [
        "Chromogranin A"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S KRYPTOR compact PLUS analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Immunofluorescent assay",
        "Time-Resolved Amplified Cryptate Emission (TRACE) technology"
    ],
    "Methodologies": [
        "Sandwich Immunoassay",
        "Automated, quantitative"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S CgA II KRYPTOR automated immunofluorescent assay for quantitative Chromogranin A determination in serum using TRACE technology",
    "Indications for Use Summary": "Automated immunofluorescent assay for quantitative determination of Chromogranin A in human serum as an aid in monitoring disease progression and treatment in patients with grade 1 and grade 2 gastroentero-pancreatic neuroendocrine tumors, to be used with other clinical methods.",
    "fda_folder": "Immunology"
}